Chronic Hepatitis B
Conditions
Interventions
A (Review):None
B (Forward-looking):None
C (Initial treatment):None
Sponsors
Henan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: The entire study enrolled 400 patients, including 300 patients in groups A and B who had received previous NAs treatment for over one year, and 100 patients in group C who were treatment-naive. Inclusion criteria: (Group A and Group B) 1. HBsAg positive or a history of CHB for more than 6 months; 2. The treatment course with NAs exceeds one year; 3. Age over 18 years old; 4. NAs Drug Categories: ETV 0.5 mg/d or ETV 1.0 mg/d or TDF 300 mg/d or LDT 600 mg/d or ADV 10 mg/d alone or in combination with LAM 100 mg/d; 5. Sign the written informed consent form. Inclusion criteria: (Group C) 1. HBsAg positive or a history of CHB for more than 6 months; 2. Treatment-naive patients: Defined as those who have not previously received approved or investigational antiviral drugs, and are now initiating ETV at 0.5 mg/day or TAF at 25 mg/day; 3. Age over 18; 4. Sign a written informed consent form.
Exclusion criteria
Exclusion criteria: 1.Co-infection with HCV/HDV/HIV; 2.Complicated with liver tumors and tumors of other organ systems; 3.Having severe kidney, cardiovascular, pulmonary or neurological diseases; 4.Requiring the use of immunotherapeutic drugs or antineoplastic drugs; 5.Patients planning to become pregnant, pregnant patients, and patients who cannot use contraception during the study; 6.Patients with a history of interferon treatment; 7.Patients with decompensated liver cirrhosis, including those with Child-Turcotte-Pugh (CTP) class B or C.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone Mineral Density(BMD);Bone Markers;Basic Biochemical Indicators;Five Hepatitis B Markers and HBV-DNA(Hepatitis B Virus Deoxyribonucleic Acid)); | — |
Countries
China
Contacts
Public ContactShang Jia
Henan Provincial People's Hospital
Outcome results
None listed